Publications by authors named "Teresa Martinez Perez"
Article Synopsis
- Ustekinumab is approved for treating ulcerative colitis (UC), and this study evaluated its long-term effectiveness and tolerability in real clinical settings.
- In a multicenter analysis of 620 UC patients, 25% discontinued treatment, with baseline anemia, steroid use, and severe disease linked to higher discontinuation rates.
- At 16 weeks, 40% of patients were in steroid-free remission, and treatment was generally safe with no adverse effects on other conditions, indicating good long-term durability for difficult-to-treat cases.
Background: Ulcerative proctitis (UP) can have a milder, less aggressive course than left-sided colitis or extensive colitis. Therefore, immunosuppressants tend to be used less in patients with this condition. Evidence, however, is scarce because these patients are excluded from randomised controlled clinical trials.
View Article and Find Full Text PDF(1) Background: Transition is a planned movement of paediatric patients to adult healthcare systems, and its implementation is not yet established in all inflammatory bowel disease (IBD) units. The aim of the study was to evaluate the impact of transition on IBD outcomes. (2) Methods: Multicentre, retrospective and observational study of IBD paediatric patients transferred to an adult IBD unit between 2017-2020.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the effects of switching from the adalimumab (ADA) originator to its biosimilars on treatment persistence, clinical efficacy, and safety in patients with inflammatory bowel disease.
- A total of 524 patients were analyzed, with some maintaining the ADA originator and others switching to biosimilars, showing similar rates of treatment discontinuation and relapse between the two groups.
- The findings concluded that switching to ADA biosimilars did not negatively impact patient outcomes compared to continuing with the ADA originator.
Introduction: The objective of this study was to assess the durability, short-term and long-term effectiveness, and safety of tofacitinib in ulcerative colitis (UC) in clinical practice.
Methods: This is a retrospective multicenter study including patients with UC who had received the first tofacitinib dose at least 8 weeks before the inclusion. Clinical effectiveness was based on partial Mayo score.
(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case−control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March−July 2020 included in the ENEIDA of GETECCU.
View Article and Find Full Text PDFBackground And Aims: Clinical trials and real-life studies with ustekinumab in Crohn's disease [CD] have revealed a good efficacy and safety profile. However, these data are scarcely available in elderly patients. Therefore, we aim to assess the effectiveness and safety of ustekinumab in elderly patients with CD.
View Article and Find Full Text PDFWe aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia).
View Article and Find Full Text PDFBackground And Aims: The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life.
Methods: Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included.
Introduction: the guidewire (GW) may enter the pancreatic duct during common bile duct (CBD) cannulation attempts in endoscopic retrograde cholangiopancreatography (ERCP). After GW passage into the pancreas, the most effective maneuver for CBD cannulation and pancreatitis prevention has not been determined.
Aim: to study CBD cannulation and post-ERCP pancreatitis rates when a pancreatic stent is inserted after an unintentional GW cannulation of the pancreatic duct.
Background And Objectives: plastic biliary stents are often used after an ERCP session without complete common bile duct stones (CBDS) extraction. Sometimes, the volume of biliary drainage with these stents may be insufficient. We present our experience with the use of fully covered self-expanding metal stents (FCSEMS) in the setting of incomplete CBDS extraction.
View Article and Find Full Text PDFBackground: The frequency of allergy to drugs is 5-10% in the general population, The Shelley's test is a method in vitro for its diagnosis and it is considered positive when it is equal o greater than 20%.
Objective: To show the allergy to drugs frequency evaluated by the Shelley's Modified Test.
Material And Methods: We included 165 patients with clinical diagnosis of allergy to drugs to those who the test of Shelley's was applied modified test for one or several medicines.